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Liquid Crystal Nanodispersions Enable the Cutaneous Delivery of Photosensitizer for 
Topical PDT: Fluorescence Microscopy Study of Skin Penetration 
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Bentley*  
Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. do Café, s/n, 14040-160, Ribeirão Preto, 
SP, Brazil 
Abstract: Topical photodynamic therapy (PDT) has been applied to almost all types of nonmelanoma skin cancer and numerous superfi-
cial benign skin disorders. Strategies to improve the accumulation of photosensitizer in the skin have been studied in recent years. Al-
though the hydrophilic phthalocyanine zinc compound, zinc phthalocyanine tetrasulfonate (ZnPcSO4) has shown high photodynamic effi-
ciency and reduced phototoxic side effects in the treatment of brain tumors and eye conditions, its use in topical skin treatment is cur-
rently limited by its poor skin penetration. In this study, nanodispersions of monoolein (MO)-based liquid crystalline phases were studied 
for their ability to increase ZnPcSO4 uptake by the skin. Lamellar, hexagonal and cubic crystalline phases were prepared and identified by 
polarizing light microscopy, and the nanodispersions were analyzed by dynamic light scattering. In vitro skin penetration studies were 
performed using a Franz's cell apparatus, and the skin uptake was evaluated in vivo in hairless mice. Aqueous dispersions of cubic and 
hexagonal phases showed particles of nanometer size, approximately 224 ±10 nm and 188 ± 10 nm, respectively. In vitro skin retention 
experiments revealed higher fluorescence from the ZnPcSO4 in deeper skin layers when this photosensitizer was loaded in the hexagonal 
nanodispersion system when compared to both the cubic phase nanoparticles and the bulk crystalline phases (lamellar, cubic and hexago-
nal). The hexagonal nanodispersion showed a similar penetration behavior in animal tests. These results are important findings, suggest-
ing the development of MO liquid crystal nanodispersions as potential delivery systems to enhance the efficacy of topical PDT.
Keywords: Liquid crystalline phases, nanodispersion, skin cancer, skin penetration, photodynamic therapy, zinc phthalocyanine. 
1. INTRODUCTION 
 Topical photodynamic therapy (PDT) has been applied to al-
most every type of superficial nonmelanoma skin cancer and nu-
merous benign skin disorders [1-2]. PDT is based on the admini-
stration of a photosensitizing drug and its selective retention in 
malignant tissue and its subsequent activation by light at specific 
wavelengths, causing cell death by the production of free radicals 
and/or reactive oxygen species [3, 4]. Numerous strategies have 
been studied in recent years in attempts to improve the accumula-
tion of photosensitizers and their precursors in the skin, including 
the use of microemulsions [5], micelles [6], liposomes [7], ceramic-
based nanoparticles [8], gold nanoparticles [9], polymer nanoparti-
cles [10], dendrimers [11], invasomes [12] and liquid crystalline 
phases [13-15]. Lipophilic phthalocyanines (e.g., zinc and chloro-
aluminum compounds) have been widely used as photosensitizers 
in preclinical studies of PDT for the treatment of skin cancer [16, 
17]. In contrast, the water-soluble zinc phthalocyanine tetrasul-
fonate (ZnPcSO4) has displayed high photodynamic efficiency and 
reduced phototoxic side effects in the treatment of brain and ocular 
tumors [18]. However, with exception of a few studies [19-21], 
there is a lack of data on the application of ZnPcSO4 in PDT for 
skin cancer. 
 Their ability to control the release of drugs and their excellent 
biocompatibility make liquid crystals based on polar lipids such as 
monoolein (MO) particularly attractive as delivery matrices for the 
topical and transdermal delivery of drugs [20, 22-25], including 
prodrugs and photosensitizers in PDT for skin cancer [13, 14]. 
Moreover, liquid crystalline lipid-water phases with an inverse 
structure (reverse hexagonal and the cubic phases) can co-exist in 
equilibrium with an excess of water, forming kinetically stable 
colloidal dispersions [26]. 
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 ZnPcSO4 (MW 898.15 g/mol) presents four charged groups in 
its molecular structure, which makes the molecule hydrophilic and 
prevents its penetration into the lipophilic stratum corneum, the 
main skin barrier. The low passive penetration of the drug, there-
fore, motivates the use of nanoparticles to improve drug entry into 
deeper skin layers. Nanoparticles of cubic and hexagonal lipid-
water phases have been used for the development of controlled-
release formulations of biologically active agents in the field of 
drug delivery and have demonstrated their potential as a new topi-
cal delivery system [15]. In this context, we studied several bulk 
MO-based liquid crystalline phases and their nanodispersions in 
vitro and in vivo with respect to their ability to increase the skin 
uptake of ZnPcSO4, a crucial condition for the effectiveness of 
topical PDT for skin cancer. 
2. EXPERIMENTAL PROCEDURE 
2.1. Materials  
 A commercial grade of monoolein (MO) (Myverol 18:99) was 
purchased from Danisco Ingredients (Copenhagen, Denmark) and 
used as received. Oleic acid (OA) was obtained from Sigma (St. 
Louis, MO, USA). Polysorbate 80 and citrate buffer were provided 
by BDH Chemical, Ltd. (Poole, UK). Zinc phthalocyanine tetrasul-
fonate (ZnPcSO4) was purchased from Frontier Scientific Inc., 
(Logan, UT). Milli-Q water was obtained by a Millipore system 
(Millipore Corporation). Sephadex LH20 was provided by GE 
Healthcare, methanol was acquired from Bdick & Jackson (B & J 
ACS / HPLC Certified Solvent) and poloxamer 407 was purchased 
from BASF (São Paulo, Brazil). 
2.2. Preparations of Bulk Gels of Lyotropic Liquid Crystalline 
Phases and Polarized Light Microscopy Characterization  
 The bulk gels of lyotropic liquid crystalline phases were devel-
opment based on experiences of the research group in field of liquid 
crystalline phases technology [13, 15, 34]. The lamellar and cubic 
phase gels was prepared by first melting MO at 42ºC followed by 
the addition of water at 10% and 30% (w/w), respectively. The 
hexagonal phase was prepared adding OA in the proportion 
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MO:OA:water of 77:5:18 (w/w/w). The preparations were loaded 
with 0.5 mg of ZnPcSO4/3g formulation after solubilization in the 
aqueous phase. All preparations were kept at room temperature and 
protected from the light for 24 h. The formulations were examined 
through a polarized light microscope (Axioplan 2 Image Pol micro-
scope, Carl Zeiss, Oberkochen, Germany) to characterize their liq-
uid crystalline structure. 
2.3. Nanodispersion Obtainment and Characterization  
 The cubic and hexagonal phase gels, obtained as described 
above, were dispersed by vortex-mixing in a pH 6.0 citrate buffer 
containing 1% or 1.5% of poloxamer in the proportion 10:90 
(gel:buffer), respectively. The dispersions were loaded with 
ZnPcSO4 at the same concentration used for the bulk gels. The 
resulting dispersions were sonicated in an ice bath for 2 min, 
centrifuged at 1,901  g for 10 min and then filtered through a 0.8 
m membrane [21]. The mean diameter and particle size distribu-
tion of each dispersion were determined using a dynamic light scat-
tering system (Zetasizer, NanoZS, Malvern, UK) at 90º with a He-
Ne laser. For this procedure, samples were first diluted in particle-
free purified water, and the measurements were performed at 25ºC. 
 The degree of encapsulation was determined by size exclusion 
chromatography. Samples (500 L) were loaded on a Sephadex 
LH-20 column (3.5 cm in diameter with a column packing length of 
17 cm) and eluted using purified water as the mobile phase. The 
eluted fractions were monitored by turbidity measurements at 410 
nm using a FEMTO 800XI spectrophotometer (Sao Paulo, Brazil). 
Aliquots of 1 mL of each fraction were lyophilized then solubilized 
in 3 mL of methanol and assayed for ZnPcSO4 content by 
spectrofluorimetry (exc = 640 nm, em = 730 nm), as described in 
spectrofluorimentric assay section. The encapsulation efficiency 
(EE) was calculated using the following equation:  
EE = M1Mt
x100

where, M1 is the amount of ZnPcSO4 encapsulated in the 
nanoparticles and Mt is the amount of ZnPcSO4 used in the 
formulation. The experiments were performed in triplicate. 
 The lamellar nanodispersions not was evaluated in this research 
because it has been studied by ours research group and in the future 
it may be demonstrated as promising skin delivery enhancer of a 
several lipophilic and hydrophilic photosensitizers. 
2.4. In vitro Skin Penetration Study  
 ZnPcSO4 topical delivery systems were assessed in an in vitro 
model of porcine ear skin, as previously described [24] in order to 
evaluate the skin retention of ZnPcSO4 from nanodispersions of 
MO-based liquid crystalline hexagonal and cubic phases and the 
corresponding cubic, lamellar and hexagonal phase bulk gels. 
 The skin of a freshly excised porcine ear was carefully dis-
sected (ensuring that the subcutaneous fat was completely re-
moved), dermatomized at 500 m (Dermaton, Nouvag, Switzer-
land) and stored at -20º C. On the day of the experiment, the skin 
was mounted in a Franz diffusion cell (with a diffusion area of 0.8 
cm2) with the stratum corneum (SC) facing the donor compartment 
(where 100 L of the test formulation was applied) and the dermis 
facing the receptor compartment, which was filled with 3.0 mL of 
receptor medium (100 mM phosphate buffer, pH 7.2 ± 0.2, contain-
ing 2% Polysorbate 80). The receptor phase was under constant 
stirring at 400 rpm and held at a 37° C (± 0.5) by a water jacket for 
6 h. At the end of the experiment, skin surfaces were thoroughly 
washed with distilled water to remove excess formulation and care-
fully wiped with tissue paper. The whole skin samples were used 
for fluorescence microscopy analysis. Aliquots of receptor solution 
were assayed by spectrofluorimetric method for ZnPcSO4.
2.5. Spectrofluorimetric Assay for ZnPcSO4
 ZnPcSO4 present in the receptor solution and samples from size 
exclusion chromatography was assayed by spectrofluorimetry (exc
= 640 nm, em = 730 nm) using a Hitachi F-4500 fluorescence spec-
trophotometer (Tokyo, Japan). Analytical method was developed 
and evaluated with respect to linearity, precision, accuracy, limits 
of detection (LOD), and lower limit of quantification (LLOQ). The
linearity of the assay was determinate using methanolic standard 
solution with concentration ranging from 0.25–10.00 g/mL, and 
the calibration curve was y=0.1447x+0.0025 (r=0.999). The error 
and accuracy of the method showed a variation coefficient not 
greater than 0.93% and 96%, respectively. The lower limits of 
quantification and detection of the method were 0.25 g/mL and 
0.08 g/mL, respectively. 
2.6. In vivo Skin Penetration Studies 
 These experiments were performed using six female hairless 
mice (strain HRS/J, Jackson Laboratories, Bar Harbor, ME, USA). 
One hundred microliters of MO-based hexagonal dispersion formu-
lation was applied to the skin on the dorsal region of the hairless 
mice over an area of 1.5 cm2, delimited by a template. After 6 h of 
application, the animals were euthanized with carbon dioxide vapor 
following the protocol previously authorized by the University of 
São Paulo Animal Care and Use Committee (Authorization num-
ber: 10.1.160.53.0), and the treated skin regions were dissected.  
2.7. Visualization of Cutaneous Penetration of Photosensitizer 
by Fluorescence Microscopy  
 The skin samples obtained from the in vitro and in vivo experi-
ments were embedded in a matrix of Tissue-Tek® O.C.T.TM com-
pound (Sakura, Zoeterwoude, The Netherlands), frozen at -17ºC 
and sectioned to the skin surface into vertical slices 40 m thick 
using a cryostat (CM 1900, LEICA, Nussloch, Germany). The pres-
ence of ZnPcSO4 and its distribution in the skin layers was visual-
ized by fluorescence microscopy (Axioskop 2 plus, Carl Zeiss, 
Göttingen, Germany) using 640 nm and 730 nm band-pass excita-
tion and emission filters, respectively (filter Set 50, Carl Zeiss). 
Images were recorded with a light-sensitive charge-coupled device 
digital camera (AxioCam HR, Göttingen, Carl Zeiss) using identi-
cal sensitivity and exposure settings.  
3. RESULTS 
 We investigated the enhanced skin penetration of a water-
soluble zinc phthalocyanine provided by MO-based liquid crystal-
line formulations and their nanodispersions. Bulk gels of lamellar, 
cubic and hexagonal crystalline phases were initially identified by 
light microscopy with crossed polarizer, as well as the cubic and 
hexagonal phase dispersion systems. Polarized light microscopy 
observation showed patterned structures and birefringent textures of 
lamellar and hexagonal phases, such as the Maltese cross (Fig. 1A)
and an angular texture (Fig. 1B), respectively. Photomicrographs of 
the nanodispersions of the cubic and hexagonal phases are shown in 
Fig. (1C) and (1D), respectively and it is in agreement with Lopes 
et al., 2007 [25]. 
 The particle size distribution, zeta potential and polydispersity 
of both the cubic and hexagonal phase nanodispersions loaded with 
ZnPcSO4 are listed in Table 1. The light scattering analysis demon-
strated the presence of nanosized particles with sizes of 224 ±10 nm 
and 188 + 10 nm for the cubic and hexagonal nanodispersions, 
respectively. Both nanodispersion present negative zeta potential 
values, of which, hexagonal phase showed higher negative charge. 
The polidispersity index indicate monodispersed characteristic for 
both nanodispersions. The encapsulation degrees assessed by size 
exclusion chromatography were 50.1% and 38.5% (+ 2) ZnPcSO4
loading in the hexagonal and cubic nanodispersion systems, respec-
tively.  
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 In vitro ZnPcSO4 skin penetration is illustrated in Fig. (2). After 
6 h of application, the MO-based hexagonal nanodispersion system 
promoted a greater penetration of photosensitizer in the deeper skin 
layers (Fig. 2F) compared with the cubic phase nanodispersion 
(Fig. 2E) and the bulk crystalline phases, i.e., the lamellar (Fig. 
2C), cubic (Fig. 2C) and hexagonal phases (Fig. 2D).  
 Due to the improved penetration effect, the hexagonal nanodis-
persion was selected for a subsequent in vivo penetration study. 
(Fig. 3) shows sections of untreated skin with and without fluores-
cence excitation (Fig. 3A and B, respectively) and skin treated with 
the hexagonal nanodispersion system photographed immediately 
and 50 seconds after the application of the excitation light (Fig. 3C
and 3D, respectively). The in vivo treatment with the hexagonal 
nanodispersion loaded with ZnPcSO4 yielded an increased fluores-
cence in deeper skin layers. (Fig. (3A) and (3B)) are photomicro-
graphs of untreated skin photographed without and with fluores-
cence excitation, respectively; a photomicrograph of skin treated 
with the hexagonal nanodispersion system was obtained in the same 
way (Fig. 3C). No fluorescence was observed in the untreated skin 
(Fig. 3B); however, the skin treated with the hexagonal nanodisper-
sion system loaded with ZnPcSO4 emitted a characteristic red light. 
DISCUSSION 
 The water-soluble ZnPcSO4 has shown high photodynamic 
efficiency and reduced phototoxic side effects in the treatment of 
brain and ocular tumors [18, 27]. However, there is a lack data for 
its application in topical PDT for skin cancer. Aqueous dispersions 
of liquid crystalline phases of MO were previously obtained and 
characterized [23], but the use of a hexagonal phase dispersion as a 
colloidal carrier of ZnPcSO4 for topical PDT is a new application in 
this field. Here, we describe the preparation, characterization and 
skin uptake of ZnPcSO4 delivered by a liquid crystalline phase MO 
nanodispersion.  
 Fig. (1) shows characteristic patterns of birefringent liquid crys-
talline phases under polarized light. The hexagonal phase displayed 
an angular texture [28]. The lamellar phase showed distinct woven 
structures and/or a mosaic or Maltese cross pattern, whereas the 
stiff transparent cubic phase was nonbirefringent [28, 29]. The 
presence of ZnPcSO4 did not change the liquid crystalline structure 
of these phases. 
 Liquid crystalline nanodispersions have many important charac-
teristics for drug delivery due to their drug solubilization capability  
Fig. (1). Characterization of the liquid crystalline phases and their dispersions by polarized light microscopy. (a) Lamellar phase bulk gel; (b) hexagonal phase 
bulk gel; (c) cubic phase nanodispersion and (d) hexagonal phase nanodispersion.  
Table 1. Caracterization of Cubic and Hexagonal Nanoparticles from Particle Size Distribution, Zeta Potencial and Polidispersity
Preparation Particle Size Distribution Zeta Potencial Polidispersity*
Cubic nanodispersion 224 ±10 nm -16.7 mV 0.37 
Hexagonal nanodispersion 188 ±10 nm -23.0 mV 0.21  
* Polidispersity index, meaning the measurement of the homogeneity of a dispersion, ranging from 0.0 (monodisperse) to 1.0 (very heterogeneous). 
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Fig. (2). Microscopic evaluation after in vitro skin treatment for 6 h using 
formulations loaded with ZnPcSO4. (a) light microscopy of untreated skin 
section, (b) fluorescence microscopy of skin treated with lamellar phase 
bulk gel (absence of light), (c) fluorescence microscopy of skin treated with 
cubic phase bulk gel (absence of light), (d) fluorescence microscopy of skin 
treated with hexagonal phase bulk gel, (e) fluorescence microscopy of skin 
treated with cubic phase nanodispersion (low intensity of light) and (f) fluo-
rescence microscopy of skin treated with hexagonal phase nanodispersions 
(high intensity of light). Sections were visualized using 640 nm (excitation) 
and 730 nm (emission) band-pass filters through a 10X objective. 
and release properties, which can improve skin penetration by the 
drug [30]. The sonication of cubic and hexagonal phase with an 
excess of the aqueous phase to form nanodispersion systems re-
sulted in milky and low-viscosity dispersions, as reported previ-
ously [15]. In order to evaluate the influence of poloxamer in cubic 
and hexagonal phase structures, the formulations were observed by 
polarized light microscopy before and after addition of poloxamer. 
The presence of poloxamer did not disrupt the cubic or hexagonal 
phase structures and additionally yielded a stable nanodispersion in 
the presence of photosensitizer. Increasing the poloxamer concen-
tration to 1.5% in the hexagonal nanodispersion system caused a 
discrete reduction in particle size as determined by light scattering, 
which is in agreement with previously published results [31, 32].  
 Demonstrating the penetration-enhancing effect of MO, a pre-
vious study reported an increase of 5-aminolevulinic acid (5-ALA)  
Fig. (3). Microscopic evaluation after in vivo skin treatment for 6 h using a 
hexagonal nanodispersion containing the photosensitizer. (a) Light micros-
copy of untreated skin, (b) fluorescence microscopy of untreated skin, (c)
fluorescence microscopy of skin treated with the hexagonal nanodispersion. 
Sections were visualized using 640 nm (excitation) and 730 nm (emission) 
band-pass filters through a 10X objective. 
in vitro penetration and in vivo protoporphyrin IX accumulation in 
hairless mouse skin with the use of various concentrations of MO in 
propylene glycol in comparison with the control solutions [32].  
 MO structured in a cubic phase gel (70:30, MO:water) provided 
an increase of in vitro and in vivo skin uptake for 5-ALA and its 
ester derivatives (hexyl, octyl and decyl esters), m-tetrahydroxy-
phenylchlorin and an in vivo increase of protoporphyrin IX accumu-
lation [33]. Similarly, compared to standard ointments, a similar 
effect of in vivo protoporphyrin IX accumulation was observed 
when an MO cubic phase was used as a delivery vehicle for 5-ALA 
and methyl-5-ALA [13]. However, MO-based cubic and hexagonal 
phase nanodispersions remain an unexplored pathway to enhanced 
PDT for skin cancer, and only the influence of photosensitizers on 
their internal liquid crystalline structure was recently studied [15].  
 Although a prior study reported that cubic and lamellar phases 
provided the highest drug retention in the whole skin (epidermis 
plus dermis) in both in vitro and in vivo studies compared with the 
control formulation of a hydroxyethyl cellulose gel [19], in the 
present work, greater in vitro delivery of ZnPcSO4 into the deeper 
skin layers was observed when the hexagonal nanodispersion sys-
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tem was applied in comparison with the other liquid crystalline 
phases (Fig. 2). Comparing the cubic and hexagonal phases, there 
are differences between these crystalline phases that may explain 
the present findings. The delivery of compounds into deeper skin 
layers has been shown to depend on the system used and the MO 
concentration; a higher delivery of vitamin K to the epidermis plus 
dermis was obtained using a nanodispersion of MO-based hexago-
nal phase when compared to a Vaseline solution [25], and MO, the 
main structural lipid of the nanodispersion, is a penetration enhan-
cer that has already been demonstrated to increase skin penetration 
of peptide drugs such as cyclosporine in a concentration-dependent 
manner [24]. Alternatively, the presence of OA in the MO-based 
hexagonal nanodispersion system may have been responsible for 
the greater penetration of the photosensitizer into the deeper layers 
of skin when compared with the cubic phase nanodispersion, as the 
penetration-enhancing effect of OA is well known [16, 34]. Fur-
thermore, the small particle size of the hexagonal phase nanodisper-
sion should improve the partitioning of ZnPcSO4 into the stratum 
corneum. In vivo penetration results showed higher fluorescence by 
ZnPcSO4 in the deeper skin layers of hairless mice when the hex-
agonal phase nanodispersion was used (Fig. 3C) compared with the 
control skin without treatment, indicating that a biodistribution of 
this photosensitizer in the epidermis and the deeper skin layers was 
achieved.  
 Considering the barrier effect of the stratum corneum and the 
limitations of ZnPcSO4 in overcoming this barrier, the hexagonal 
phase nanodispersion provided a skin delivery system for this sub-
stance in a way that can enable its use in topical PDT. The results 
obtained encourage future studies to ascertain whether our formula-
tions can improve the efficacy of topical PDT for skin cancer.
CONCLUSIONS 
 Nanodispersions of MO-based liquid crystalline hexagonal and 
cubic phases increased the in vitro skin penetration of ZnPcSO4,
more than the corresponding cubic, lamellar and hexagonal phase 
bulk gels.
 Our results provide the possibility of a new application for 
ZnPcSO4, improving the effectiveness of photodynamic therapy by 
utilizing a nanosized dispersion based on MO-liquid crystalline 
phases to deliver photosensitizing drugs into the deeper skin layers, 
where cancer and non-neoplastic diseases occur. Further studies 
will evaluate the photodynamic efficiency and phototoxic side ef-
fects in topical PDT and photodiagnostic assays for skin cancer 
using skin tumor cell lines and animal models of skin cancer. 
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